-
Je něco špatně v tomto záznamu ?
Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors
E. Javorkova, N. Matejckova, A. Zajicova, B. Hermankova, M. Hajkova, P. Bohacova, J. Kossl, M. Krulova, V. Holan,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2006-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2010-03-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-03-01 do Před 1 rokem
- MeSH
- amyotrofická laterální skleróza imunologie MeSH
- buňky kostní dřeně imunologie MeSH
- cytokiny metabolismus MeSH
- imunologické faktory farmakologie MeSH
- imunomodulace MeSH
- leukocyty mononukleární účinky léků imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mezenchymální kmenové buňky imunologie MeSH
- mitogeny farmakologie MeSH
- T-lymfocyty pomocné-indukující účinky léků imunologie MeSH
- TNF-alfa biosyntéza MeSH
- zdraví dobrovolníci pro lékařské studie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Pathogenesis of amyotrophic lateral sclerosis (ALS) involves several mechanisms resulting in a shift from a neuroprotective to a neurotoxic immune reaction. A promising tool for ALS treatment is represented by mesenchymal stem cells (MSCs), which possess both regenerative potential and immunomodulatory properties. In this study, we aimed to compare the immunomodulatory properties of MSCs isolated from the bone marrow of patients suffering from ALS and healthy donors. Moreover, the influence of proinflammatory cytokines on the immunoregulatory functions of MSCs was also evaluated. We found that MSCs from ALS patients and healthy donors comparably affected mitogen-stimulated peripheral blood mononuclear cells and reduced the percentage of T helper (Th)1, Th17 and CD8+CD25+ lymphocytes. These MSCs also equally increased the percentage of Th2 and CD4+FOXP3+ T lymphocytes. On the other hand, MSCs from ALS patients decreased more strongly the production of tumour necrosis factor-α than MSCs from healthy donors, but this difference was abrogated in the case of MSCs stimulated with cytokines. Significant differences between cytokine-treated MSCs from ALS patients and healthy donors were detected in the effects on the percentage of CD8+CD25+ and CD4+FOXP3+ T lymphocytes. In general, treatment of MSCs with cytokines results in a potentiation of their effects, but in the case of MSCs from ALS patients, it causes stagnation or even restriction of some of their immunomodulatory properties. We conclude that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines. Graphical Abstract Treatment of mesenchymal stem cells (MSCs) with cytokines results in a potentiation of their effects, but in the case of MSCs from amyotrophic lateral sclerosis (ALS) patients, it causes stagnation (an equal reduction of the percentage of CD8+CD25+ T lymphocytes) or even restriction (no increase of proportion of CD4+FOXP3+ T lymphocytes) of some of their immunomodulatory properties. It means that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025838
- 003
- CZ-PrNML
- 005
- 20201222155501.0
- 007
- ta
- 008
- 201125s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11481-018-9812-7 $2 doi
- 035 __
- $a (PubMed)30242613
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Javorkova, Eliska $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. eliska.javorkova@iem.cas.cz. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic. eliska.javorkova@iem.cas.cz.
- 245 10
- $a Immunomodulatory Properties of Bone Marrow Mesenchymal Stem Cells from Patients with Amyotrophic Lateral Sclerosis and Healthy Donors / $c E. Javorkova, N. Matejckova, A. Zajicova, B. Hermankova, M. Hajkova, P. Bohacova, J. Kossl, M. Krulova, V. Holan,
- 520 9_
- $a Pathogenesis of amyotrophic lateral sclerosis (ALS) involves several mechanisms resulting in a shift from a neuroprotective to a neurotoxic immune reaction. A promising tool for ALS treatment is represented by mesenchymal stem cells (MSCs), which possess both regenerative potential and immunomodulatory properties. In this study, we aimed to compare the immunomodulatory properties of MSCs isolated from the bone marrow of patients suffering from ALS and healthy donors. Moreover, the influence of proinflammatory cytokines on the immunoregulatory functions of MSCs was also evaluated. We found that MSCs from ALS patients and healthy donors comparably affected mitogen-stimulated peripheral blood mononuclear cells and reduced the percentage of T helper (Th)1, Th17 and CD8+CD25+ lymphocytes. These MSCs also equally increased the percentage of Th2 and CD4+FOXP3+ T lymphocytes. On the other hand, MSCs from ALS patients decreased more strongly the production of tumour necrosis factor-α than MSCs from healthy donors, but this difference was abrogated in the case of MSCs stimulated with cytokines. Significant differences between cytokine-treated MSCs from ALS patients and healthy donors were detected in the effects on the percentage of CD8+CD25+ and CD4+FOXP3+ T lymphocytes. In general, treatment of MSCs with cytokines results in a potentiation of their effects, but in the case of MSCs from ALS patients, it causes stagnation or even restriction of some of their immunomodulatory properties. We conclude that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines. Graphical Abstract Treatment of mesenchymal stem cells (MSCs) with cytokines results in a potentiation of their effects, but in the case of MSCs from amyotrophic lateral sclerosis (ALS) patients, it causes stagnation (an equal reduction of the percentage of CD8+CD25+ T lymphocytes) or even restriction (no increase of proportion of CD4+FOXP3+ T lymphocytes) of some of their immunomodulatory properties. It means that MSCs from ALS patients exert comparable immunomodulatory effects to MSCs from healthy donors, but respond differently to stimulation with proinflammatory cytokines.
- 650 _2
- $a amyotrofická laterální skleróza $x imunologie $7 D000690
- 650 _2
- $a buňky kostní dřeně $x imunologie $7 D001854
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zdraví dobrovolníci pro lékařské studie $7 D064368
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x farmakologie $7 D007155
- 650 _2
- $a imunomodulace $7 D056747
- 650 _2
- $a leukocyty mononukleární $x účinky léků $x imunologie $7 D007963
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mezenchymální kmenové buňky $x imunologie $7 D059630
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mitogeny $x farmakologie $7 D008934
- 650 _2
- $a T-lymfocyty pomocné-indukující $x účinky léků $x imunologie $7 D006377
- 650 _2
- $a TNF-alfa $x biosyntéza $7 D014409
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Matejckova, Nicole $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 700 1_
- $a Zajicova, Alena $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic.
- 700 1_
- $a Hermankova, Barbora $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 700 1_
- $a Hajkova, Michaela $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 700 1_
- $a Bohacova, Pavla $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 700 1_
- $a Kossl, Jan $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 700 1_
- $a Krulova, Magdalena $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 700 1_
- $a Holan, Vladimir $u Department of Transplantation Immunology, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 4, 142 20, Prague, Czech Republic. Department of Cell Biology, Faculty of Science, Charles University, Vinicna 7, 128 43, Prague 2, Czech Republic.
- 773 0_
- $w MED00201263 $t Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology $x 1557-1904 $g Roč. 14, č. 2 (2019), s. 215-225
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30242613 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155457 $b ABA008
- 999 __
- $a ok $b bmc $g 1599983 $s 1116524
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 14 $c 2 $d 215-225 $e 20180921 $i 1557-1904 $m Journal of neuroimmune pharmacology $n J Neuroimmune Pharmacol $x MED00201263
- LZP __
- $a Pubmed-20201125